相关实验视频
Updated: Jun 25, 2025
06:00
Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
167
莫格洛西德缓解糖尿病并调节2型糖尿病小鼠的肠道微生物群
Tiantian Qin1, Yuqing Li2, Yijing Wu3
1Key Laboratory of TCM Neuro-metabolism and Immunopharmacology of Guangxi Education Department, Guangxi University of Chinese Medicine.
Biological & pharmaceutical bulletin
|May 29, 2024
概括
天然化合物莫格洛,通过调节肠道细菌和减少炎症,有效治疗2型糖尿病. 这项研究显示了其作为糖尿病管理治疗剂的潜力.
科学领域:
- 药理学和自然产品的研究.
- 胃肠道学和微生物组研究
- 代谢疾病和内分泌学
背景情况:
- 来自Siraitia grosvenorii的Mogroside具有已知的低血糖和肠道微生物群调节性质.
- 与肠道微生物群调节和代谢性内毒症相关联的确切机制仍然不清楚.
研究的目的:
- 调查摩格洛的低血糖作用的潜在机制,重点关注其在调节肠道菌群和减轻代谢性内毒症中的作用.
- 评估摩格洛对葡萄糖代谢,炎症标志物和肠道微生物群组成的影响,在2型糖尿病 (T2DM) 的小鼠模型中.
主要方法:
- 在昆明小鼠中诱导了2型糖尿病,使用高脂肪饮食和 estreptozotocin.
- 小鼠接受了不同剂量的摩格洛或皮奥格利塔治疗.
- 评估包括肝脏葡萄糖代谢,血内毒素,炎症标志物 (CD14,TLR4 mRNA) 和通过16S rDNA测序的肠道微生物组成.
主要成果:
- 在T2DM小鼠中,Mogroside显著改善了肝脏葡萄糖代谢,并降低了血内毒素水平.
- 用莫格洛治疗导致CD14和托尔类受体4 (TLR4) mRNA水平降低,表明炎症减少.
- 莫格洛调节了肠道微生物群,减少了菌体和蛋白质细菌的丰富性,同时增加了细菌体.
结论:
- 摩格洛西德通过调节肠道菌群和增强肠道粘膜屏障,证明了缓解2型糖尿病的有效性.
- 这些发现表明,mogroside具有作为T2DM治疗剂的潜力,同时作为降糖化合物和肠道微生物群调节剂.
相关概念视频
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173